NASDAQ:SELB - Selecta Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.75
  • Forecasted Upside: 159.62 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.60
▲ +0.42 (19.27%)
1 month | 3 months | 12 months
Get New Selecta Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SELB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SELB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$6.75
▲ +159.62% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Selecta Biosciences in the last 3 months. The average price target is $6.75, with a high forecast of $13.00 and a low forecast of $2.50. The average price target represents a 159.62% upside from the last price of $2.60.
Buy
The current consensus among 7 contributing investment analysts is to buy stock in Selecta Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/30/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/29/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/21/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/21/2020

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/9/2020Cantor FitzgeraldReiterated RatingOverweightLow
i
Rating by K. Kluska at Cantor Fitzgerald
10/5/2020HC WainwrightLower Price TargetBuy$10.00 ➝ $6.00Low
i
Rating by Ram Selvaraju at HC Wainwright
10/1/2020MizuhoDowngradeBuy ➝ Neutral$7.00 ➝ $2.50High
i
Rating by Difei Yang at Mizuho
10/1/2020William BlairDowngradeOutperform ➝ Market PerformHigh
i
Rating by R. Prasad at William Blair
8/7/2020MizuhoReiterated RatingBuy$7.00Medium
i
Rating by Difei Yang at Mizuho
8/7/2020Canaccord GenuityReiterated RatingBuyMedium
i
7/6/2020Canaccord GenuityReiterated RatingBuyLow
i
6/18/2020HC WainwrightReiterated RatingBuy$10.00High
i
Rating by Ram Selvaraju at HC Wainwright
6/18/2020Stifel NicolausReiterated RatingHoldHigh
i
Rating by Derek Archila at Stifel Nicolaus
6/18/2020Needham & Company LLCReiterated RatingBuy$5.00Medium
i
Rating by Chad Messer at Needham & Company LLC
6/16/2020Canaccord GenuityReiterated RatingBuy$13.00High
i
6/12/2020Needham & Company LLCReiterated RatingBuy$5.00High
i
Rating by Chad Messer at Needham & Company LLC
6/12/2020Stifel NicolausDowngradeBuy ➝ Hold$4.00High
i
Rating by Derek Archila at Stifel Nicolaus
6/12/2020HC WainwrightBoost Price TargetBuy$8.00 ➝ $10.00High
i
Rating by R. Selvaraju at HC Wainwright
6/10/2020MizuhoReiterated RatingBuy$7.00Low
i
5/7/2020Stifel NicolausReiterated RatingBuy$4.00High
i
Rating by Derek Archila at Stifel Nicolaus
5/7/2020Needham & Company LLCReiterated RatingBuy$5.00High
i
5/7/2020William BlairReiterated RatingBuyHigh
i
Rating by R. Prasad at William Blair
4/28/2020HC WainwrightInitiated CoverageBuy$8.00High
i
Rating by R. Selvaraju at HC Wainwright
3/13/2020Canaccord GenuityReiterated RatingBuyHigh
i
3/12/2020Stifel NicolausReiterated RatingBuy$4.00High
i
Rating by Derek Archila at Stifel Nicolaus
2/18/2020MizuhoReiterated RatingBuy$4.00 ➝ $7.00High
i
1/29/2020Cantor FitzgeraldInitiated CoverageOverweight$10.00Low
i
Rating by E. Merle at Cantor Fitzgerald
1/21/2020William BlairInitiated CoverageOutperformHigh
i
Rating by R. Prasad at William Blair
12/19/2019MizuhoReiterated RatingBuy$4.00Low
i
Rating by Difei Yang at Mizuho
12/19/2019Stifel NicolausReiterated RatingBuyHigh
i
11/8/2019Needham & Company LLCReiterated RatingBuy$9.00Low
i
11/8/2019Stifel NicolausReiterated RatingBuy$6.00Low
i
8/11/2019MizuhoReiterated RatingBuy$4.00Medium
i
8/9/2019Stifel NicolausReiterated RatingBuy$6.00Low
i
5/10/2019MizuhoReiterated RatingBuy$4.00Low
i
3/18/2019Canaccord GenuityLower Price TargetReduce ➝ Buy$25.00 ➝ $13.00High
i
3/15/2019Stifel NicolausReiterated RatingBuy$7.00Medium
i
Rating by Derek Archila at Stifel Nicolaus
2/5/2019Stifel NicolausSet Price TargetBuy$7.00Medium
i
Rating by Derek Archila at Stifel Nicolaus
2/4/2019MizuhoLower Price TargetBuy$4.00Low
i
1/28/2019Needham & Company LLCLower Price TargetBuy$12.00Low
i
11/9/2018UBS GroupSet Price TargetHold$6.00Medium
i
Rating by Carter Gould at UBS Group AG
11/5/2018MizuhoReiterated RatingBuy$30.00Medium
i
10/23/2018Janney Montgomery ScottReiterated RatingBuyHigh
i
Rating by Yun Zhong at Janney Montgomery Scott
10/23/2018Stifel NicolausReiterated RatingBuyMedium
i
Rating by Derek Archila at Stifel Nicolaus
10/17/2018MizuhoReiterated RatingBuy$30.00High
i
9/14/2018Stifel NicolausInitiated CoverageBuy$24.00Low
i
8/9/2018MizuhoReiterated RatingBuy$30.00High
i
7/11/2018Canaccord GenuityReiterated RatingBuy$40.00High
i
6/28/2018Canaccord GenuityReiterated RatingBuy$40.00High
i
6/27/2018Janney Montgomery ScottInitiated CoverageBuy$33.00Low
i
5/23/2018Canaccord GenuityBoost Price TargetBuy$30.00 ➝ $40.00Low
i
4/11/2018MizuhoReiterated RatingBuy$30.00High
i
2/26/2018MizuhoInitiated CoverageBuy$30.00High
i
1/18/2018Canaccord GenuityReiterated RatingBuy$30.00Low
i
Rating by John Newman at Canaccord Genuity
1/3/2018Canaccord GenuityReiterated RatingBuyHigh
i
Rating by John Newman at Canaccord Genuity
11/9/2017UBS GroupDowngradeBuy ➝ NeutralN/A
i
11/7/2017Canaccord GenuityReiterated RatingBuy$30.00N/A
i
Rating by John Newman at Canaccord Genuity
10/12/2017Canaccord GenuityBoost Price TargetBuy$25.00 ➝ $30.00N/A
i
Rating by John Newman at Canaccord Genuity
8/11/2017Canaccord GenuitySet Price TargetBuy$25.00Low
i
Rating by John Newman at Canaccord Genuity
7/26/2017Canaccord GenuitySet Price TargetBuy$25.00High
i
Rating by John Newman at Canaccord Genuity
5/13/2017Canaccord GenuitySet Price TargetBuy$25.00Low
i
Rating by John Newman at Canaccord Genuity
3/30/2017UBS GroupReiterated RatingBuy ➝ Buy$26.00N/A
i
3/28/2017Needham & Company LLCReiterated RatingBuy$28.00High
i
12/9/2016UBS GroupReiterated RatingBuy$19.00 ➝ $29.00N/A
i
Rating by Jeffrey Hung at UBS Group AG
12/8/2016Stifel NicolausReiterated RatingBuy$23.00 ➝ $32.00N/A
i
Rating by Thomas Shrader at Stifel Nicolaus
12/6/2016Canaccord GenuitySet Price TargetBuy$25.00N/A
i
Rating by John Newman at Canaccord Genuity
11/12/2016Canaccord GenuitySet Price TargetBuy$25.00N/A
i
Rating by John Newman at Canaccord Genuity
7/18/2016Needham & Company LLCInitiated CoverageBuy$28.00N/A
i
7/18/2016Canaccord GenuityInitiated CoverageBuy$20.00N/A
i
7/18/2016UBS GroupInitiated CoverageBuy$19.00N/A
i
7/18/2016Stifel NicolausInitiated CoverageBuy$23.00N/A
i
(Data available from 10/21/2015 forward)
Selecta Biosciences logo
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that has completed Phase II clinical trials for the treatment of chronic refractory gout. It also engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. The company has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., BIND Therapeutics, Inc., Asklepios BioPharmaceutical, Inc., and Sarepta Therapeutics, Inc. Selecta Biosciences, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $2.60
$2.25
$2.80

50 Day Range

MA: $2.26
$1.64
$2.64

52 Week Range

Now: $2.60
$1.28
$4.83

Volume

9,230,137 shs

Average Volume

1,614,178 shs

Market Capitalization

$278.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3